A novel defined TLR3 agonist as an effective vaccine adjuvant.

Saved in:

Bibliographic Details
Title:	A novel defined TLR3 agonist as an effective vaccine adjuvant.
Authors:	Ko KH; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea.; Interdisciplinary Program in Genetic Engineering, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea., Cha SB; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea., Lee SH; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea., Bae HS; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea., Ham CS; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea., Lee MG; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea., Kim DH; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea., Han SH; Interdisciplinary Program in Genetic Engineering, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea.; Department of Oral Microbiology and Immunology, and Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Republic of Korea.
Source:	Frontiers in immunology [Front Immunol] 2023 Jan 24; Vol. 14, pp. 1075291. Date of Electronic Publication: 2023 Jan 24 (Print Publication: 2023).
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1664-3224
DOI:	10.3389/fimmu.2023.1075291